

Homie Razavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3668642/publications.pdf>

Version: 2024-02-01

89
papers

23,908
citations

87888

38
h-index

49909

87
g-index

90
all docs

90
docs citations

90
times ranked

35534
citing authors

#	ARTICLE	IF	CITATIONS
1	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
2	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	3.9	14
3	Polaris Observatoryâ€”supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis. <i>Antiviral Therapy</i> , 2022, 27, 135965352210831.	1.0	3
4	The Payer License Agreement, or â€œNetflix model,â€ for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition. <i>Liver International</i> , 2022, 42, 1503-1516.	3.9	4
5	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	2.0	14
6	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.7	114
7	Opportunistic coâ€screening for <scp>HCV</scp> and <scp>COVID</scp>â€19â€related services: A creative response with a need for thoughtful reflection. <i>Liver International</i> , 2022, 42, 960-962.	3.9	7
8	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
9	The costâ€effectiveness of hepatitis C virus elimination in lowâ€and middleâ€income countries. <i>Journal of Viral Hepatitis</i> , 2021, 28, 445-445.	2.0	4
10	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 169-184.	8.1	24
11	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVIDâ€19. <i>Liver International</i> , 2021, 41, 2024-2031.	3.9	9
12	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. <i>ELife</i> , 2021, 10, .	6.0	50
13	Progress towards hepatitis C virus elimination in highâ€income countries: An updated analysis. <i>Liver International</i> , 2021, 41, 456-463.	3.9	81
14	Global timing of hepatitis C virus elimination in highâ€income countries. <i>Liver International</i> , 2020, 40, 522-529.	3.9	147
15	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	3.9	24
16	Nonalcoholic fatty liver disease burden: Australia, 2019â€2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1628-1635.	2.8	68
17	Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. <i>PLoS ONE</i> , 2020, 15, e0237525.	2.5	8
18	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. The Lancet Gastroenterology and Hepatology, 2020, 5, 948-953.	8.1	24
20	Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Network Open, 2020, 3, e204192.	5.9	17
21	Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver International, 2020, 40, 1507-1507.	3.9	0
22	Burden of nonalcoholic fatty liver disease in Canada, 2019â€“2030: a modelling study. CMAJ Open, 2020, 8, E429-E436.	2.4	42
23	Modelling NAFLD disease burden in four Asian regionsâ€”2019â€“2030. Alimentary Pharmacology and Therapeutics, 2020, 51, 801-811.	3.7	92
24	A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Services Research, 2020, 20, 249.	2.2	3
25	Editorial: increasing burden of nonalcoholic fatty liver diseaseâ€”a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	3.7	0
26	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International, 2020, 40, 1545-1555.	3.9	37
27	Global prevalence of hepatitis C virus in children in 2018: a modelling study. The Lancet Gastroenterology and Hepatology, 2020, 5, 374-392.	8.1	80
28	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. PLoS ONE, 2020, 15, e0232186.	2.5	3
29	Global Epidemiology of Viral Hepatitis. Gastroenterology Clinics of North America, 2020, 49, 179-189.	2.2	89
30	Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model â€” Tashkent, Uzbekistan, December 6, 2019â€“March 15, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1161-1165.	15.1	9
31	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
32	Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. The Lancet Gastroenterology and Hepatology, 2019, 4, 794-804.	8.1	68
33	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52
34	Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Brazilian Journal of Infectious Diseases, 2019, 23, 182-190.	0.6	37
35	Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World Journal of Gastroenterology, 2019, 25, 1327-1340.	3.3	13
36	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	8.1	370

#	ARTICLE	IF	CITATIONS
37	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 83-92.	2.0	58
38	Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. <i>Central European Journal of Public Health</i> , 2019, 27, 93-98.	1.1	4
39	Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w20026.	1.6	9
40	Nonalcoholic fatty liver disease burden in Switzerland 2018-2030. <i>Swiss Medical Weekly</i> , 2019, 149, w20152.	1.6	12
41	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. <i>Swiss Medical Weekly</i> , 2019, 149, w14694.	1.6	7
42	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
43	The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. <i>Health Policy and Planning</i> , 2018, 33, 528-538.	2.7	34
44	Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. <i>Acta Clinica Belgica</i> , 2018, 73, 50-53.	1.2	6
45	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.	7.3	1,474
46	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. <i>PLoS ONE</i> , 2018, 13, e0209374.	2.5	12
47	The hepatitis B epidemic and the urgent need for cure preparedness. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 517-518.	17.8	20
48	Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030. <i>PLoS ONE</i> , 2018, 13, e0200750.	2.5	6
49	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. <i>Seminars in Liver Disease</i> , 2018, 38, 181-192.	3.6	185
50	HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. <i>PLoS ONE</i> , 2018, 13, e0202109.	2.5	24
51	Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission - Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 599.	8.1	21
52	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
53	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
54	Nonalcoholic fatty liver disease burden in Saudi Arabia and United Arab Emirates, 2017-2030. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 211.	1.1	77

#	ARTICLE	IF	CITATIONS
55	Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236.	2.8	61
56	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
57	Eliminaci3n de la hepatitis C en Espa+a: adaptaci3n de un modelo matem3tico de salud p3blica partiendo del plan estrat3gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina Cl3nica</i> , 2017, 148, 277-282.	0.6	24
58	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17006.	30.5	354
59	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Cl3nica (English)</i> Tj ETQq1 1 0.784314 rgBT6/Overlook	3.1	4
60	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
61	Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. <i>Hepatology International</i> , 2017, 11, 509-516.	4.2	4
62	Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 466-472.	2.8	10
63	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. <i>Swiss Medical Weekly</i> , 2017, 147, w14543.	1.6	12
64	Making the case for looking beyond <sc>WHO</sc> estimates for the global burden of hepatitis C and B. <i>Journal of Viral Hepatitis</i> , 2016, 23, 576-576.	2.0	3
65	Global genotype distribution of hepatitis C viral infection among people who inject drugs. <i>Journal of Hepatology</i> , 2016, 65, 1094-1103.	3.7	63
66	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389.	4.0	16
67	Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 797-808.	9.1	542
68	Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 269.	1.1	19
69	Hepatitis C virus infection in Argentina: Burden of chronic disease. <i>World Journal of Hepatology</i> , 2016, 8, 649.	2.0	4
70	Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. <i>Hepatitis Monthly</i> , 2016, 16, e37234.	0.2	44
71	Estimating <sc>HCV</sc> disease burden â€“ volume 3 (editorial). <i>Journal of Viral Hepatitis</i> , 2015, 22, 1-3.	2.0	13
72	Strategies to manage hepatitis C virus infection disease burden â€“ volume 3. <i>Journal of Viral Hepatitis</i> , 2015, 22, 42-65.	2.0	62

#	ARTICLE	IF	CITATIONS
73	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 21-41.	2.0	61
74	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in select countries â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	2.0	109
75	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 2015, 10, e0125214.	2.5	25
76	HCVâ€infectd patients need access now to new directâ€acting antiviral agents to avert liverâ€related deaths. Medical Journal of Australia, 2015, 202, 479-479.	1.7	4
77	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology, 2015, 50, 233-244.	1.5	33
78	Disease burden of chronic hepatitis C in Brazil. Brazilian Journal of Infectious Diseases, 2015, 19, 363-368.	0.6	15
79	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 2015, 145, w14221.	1.6	8
80	Burden of Disease and Cost of Chronic Hepatitis C Virus Infection in Canada. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 243-250.	1.9	131
81	Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis <sc>C</sc>-related liver disease and costs in <sc>A</sc>ustralia. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1-9.	2.8	67
82	Response to letter to the editor: Strategies to reduce <sc>HCV</sc> disease burden and <sc>HCV</sc> transmission need different models, as what works for endâ€stage liver disease may not work for <sc>HCV</sc> prevalence: a comment on the results presented in <sc>JVH</sc> Special Issue. Journal of Viral Hepatitis, 2014, 21, e169-70.	2.0	4
83	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	2.0	372
84	Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 2014, 61, S45-S57.	3.7	1,560
85	The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab Journal of Gastroenterology, 2014, 15, 45-52.	0.9	88
86	The State of US Health, 1990-2010. JAMA - Journal of the American Medical Association, 2013, 310, 591.	7.4	2,070
87	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013, 57, 2164-2170.	7.3	397
88	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
89	Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics, 2012, 15, 887-896.	2.1	60